H3-3A encodes histone variant H3.3, a key chr1 component that replaces conventional H3 in transcriptionally active regions and is incorporated into chr1 independently of DNA synthesis. In pediatric gliomas, somatic mutations in H3-3A create dominant oncogenic variants, most notably H3.3K27M in diffuse midline gliomas (DMGs) and H3.3G34R/V in hemispheric gliomas 12. The K27M mutation causes global reduction of H3K27 trimethylation across all histone H3 proteins, driving gliomagenesis through aberrant epigenetic reprogramming 1. DMGs with H3-3A K27M mutations represent aggressive grade 4 tumors with poor prognosis, though co-occurring BRAF/FGFR1 alterations define a distinct subtype with better outcomes 3. H3.3G34-mutant hemispheric gliomas show different molecular profiles including frequent ATRX mutations and MGMT promoter methylation, with intermediate survival compared to other glioma subtypes 24. Both H3.3 mutant variants disrupt PML nuclear body formation, preventing glial differentiation and creating potential therapeutic vulnerabilities 5. The H3-3A gene has been identified as a cancer driver gene across multiple tumor types 6.